BTIG Downgrades Personalis Following Tempus Acquisition
On Tuesday, BTIG downgraded Personalis Inc. (PSNL) to Neutral from Buy following its acquisition by Tempus AI (TEM). The downgrade comes as the investment firm anticipates that the transaction will proceed despite other potential takeover interests in Personalis. The move reflects confidence in Tempus' ability to complete the deal, which could reshape the landscape of cancer diagnostics. However, BTIG's decision suggests a cautious outlook on near-term performance or valuation for investors.
Topics: Biotech Investor Sentiment M&A